Alnodesertib, combined with irinotecan, targets ATM-negative metastatic colorectal cancer, showing promise in the STELLA study with favorable safety and clinical activity. The FDA's fast track ...
U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast cancer Artios is launching a global randomized Phase 2 ...
AVZO-103 targets Nectin4 and TROP2, aiming to deliver anticancer effects precisely to tumor cells, potentially reducing side effects. Fast track designation by the FDA expedites drug development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results